Indianapolis -- A new experimental drug from Indianapolis-based Eli Lilly and Co. has been found to have a risk of major bleeding, sometimes even death, a report says.
While the company's new blood thinner called prasugrel has been found to reduce the risk of heart attacks, it also has been found to have an inherent risk of major bleeding, The Indianapolis Star reported Sunday.
A three-year study into the new medication found that patients already at a high risk of bleeding could be harmed by taking the experimental drug.
In some of these patients, that typically include individuals with a history of strokes and the elderly, this increased bleeding can prove to be fatal, the report said.
A spokeswoman for the company said researchers would attempt to adjust the drug's dosage levels to prevent such side effects, but still praised the medication's positive attributes.
"This is very promising news to those with acute coronary syndrome," spokeswoman Janice Chavers told the Star of the prasugrel results.
Disclaimer: The views and investment tips expressed by investment experts on themoneytimes.com are their own, and not that of the website or its management. TheMoneyTimes advises users to check with certified experts before taking any investment decision.
Recent comments
1 day 19 hours ago
1 day 19 hours ago
1 day 20 hours ago
1 day 22 hours ago
2 days 19 hours ago
3 days 2 hours ago
3 days 2 hours ago
3 days 4 hours ago
3 days 5 hours ago
3 days 23 hours ago